administered prior to the onset of sexual activity. In general, antibody responses induced by vaccines are higher pre-puberty compared to post-puberty, a feature that has also been shown for the HPV vaccines. Currently followup data are available only up to 6.4 years, but modelling suggests that immunity may persist for 30 years. 8 Ideally, such a vaccine would be administered with other childhood vaccines, removing any link with sexual activity in the minds of parents.
The vaccines
Both Gardasil and Cervarix have shown high efficacy, approaching 100%, against HPV 16 and 18-related highgrade cervical intraepithelial neoplasia (CIN) and Gardasil has shown similar efficacy against genital warts. 8 Although superficially similar, there are differences between the two vaccines, which may turn out to be relevant. Both consist of virus-like particles (VLPs) using the L1 virus coat proteins. VLPs have the outward appearance of the actual virus and generate a powerful immune response (much stronger than natural immunity) but are harmless as they contain no DNA.
The VLPs in the two vaccines have been manufactured using different systems, and the adjuvants used are also different. While Gardasil contains aluminium hydroxyphosphate sulphate, Cervarix is adjuvanted with ASO4, which is aluminium hydroxide with monophosphoryl lipid A. The ASO4 adjuvant has been used previously in a hepatitis B vaccine (Fendrix ® ), where it was shown to generate a stronger and longer-lasting immune response than the vaccine containing aluminium hydroxide alone. 9 In this context, it is interesting that the antibody response to HPV 18 appears to be maintained at high levels for longer with Cervarix than Gardasil 9 though the clinical significance of this is still uncertain. One could speculate that higher antibody levels might translate into longer lasting immunity, a criterion weighted heavily in the UK evaluation (Table 1 ) and in a recent economic evaluation in the USA. 10 Clearly, if one vaccine required a booster after a certain length of time while the other did not, the difference in costs to a vaccination programme would be very significant. A direct comparison study of the two vaccines is underway, using a non-proprietary neutralising antibody assay; interim results should be available before the end of this year and are awaited with interest.
Cross-protection
A related issue is that of cross-protection. It had been thought unlikely that this would occur, yet both vaccines have shown early evidence of such an effect. In the extended Phase II trials at 6.4 years, Cervarix has shown 78% (95% CI 39-93) protection against incident infections with HPV 45, which is HPV 18-related, and 60% (95% CI 20-81) protection against incident infections with HPV 31, which is HPV 16-related. 11 In the interim analysis of the Phase III trial, Cervarix has shown cross-protection against persistent infections at 6 months for HPV type 45 (59.9%, 95% CI 2.6-85.2), type 31 (36.1%, 95% CI 0.5-59.5) and type 52 (31.6%, 95% CI 3.5-51.9). The extent of sustained cross-protection against persistent infections, abnormal cytology and precancerous lesions remains to be determined. A laboratory study of antibody cross-neutralisation with Gardasil suggested cross-protection against types 31, 45, 52 and 58, 8 while more recently data have been presented suggesting protection against both persistent HPV infection and CIN associated with a bank (31/33/45/52/58) of non-vaccine HPV types. 12 However, interestingly, in the Canadian Summary of Product Characteristics, dated March 2008, the level of protection against individual HPV types is given; here there is no cross-protection against HPV type 45. 13 Although the clinical significance of this is not yet known, it is interesting that there appears to be a consistently weaker effect of Gardasil on HPV 18 and its related type, 45 (see above). Cross-protection is an important issue, as it may raise the overall protection level significantly.
Other issues

Vaccinating older women
Studies are underway to evaluate the benefit of vaccinating older women (i.e. those over 25 years of age). In a group of previously HPV-negative women aged 24-45 years, recently presented data suggest that Gardasil was highly effective in preventing both persistent HPV infection and disease associated with the HPV types in the vaccine. 14 If efficacy in older women is confirmed, vaccination of a wider age range could have a more immediate impact on cervical cancer.
Need for third vaccine dose?
Is the third dose of vaccine actually necessary? A threedose schedule is complicated and particularly problematic in developing countries. Could one 'mix and match' the two vaccines to try and reap the benefits of both? We do not have answers to these questions at present but they are urgently needed.
Future of cervical screening?
In theory, an HPV vaccine could prevent almost all cervical cancer, eventually removing the need for cervical smears. It is noteworthy that the vaccines should be effective against cervical adenocarcinoma (of which a relatively higher proportion are associated with HPV 18 and 45), which is not detected effectively in current screening programmes and which appears to be increasing in incidence. There is potential for a very significant reduction in this cancer, which now accounts for up to 20% of cervical cancers. However, until the number of HPV types in the vaccine is increased, there will still be cancers not prevented by vaccination. In addition, there is at least one whole generation of women for whom the vaccines have come too late to precede sexual activity, and who will continue to require screening. It is, however, clear that screening programmes, where they exist, will need to adapt when HPV vaccination becomes widespread. It is likely that cytology will become less useful as the number of abnormalities in the population decreases, and cytologists struggle to maintain their skills. HPV testing of some kind is likely to be the way forward, but this raises many issues -not least the high transient positivity rates in women under 35 years, and the probable need for HPV typing tests, which are not yet commercially available, to monitor longterm vaccine efficacy. These are issues that will need to be addressed in the next 15 years in the UK.
Vaccinating boys
Data on efficacy in men are awaited, as the issue of whether to vaccinate boys as well as girls is still under debate. Most mathematical models suggest that vaccination of girls alone is the most cost-effective strategy, assuming high uptake amongst girls. However, if boys are not vaccinated, men who have sex with men (MSM), and who are at increased risk of HPV infections and anal cancer, will not benefit from the vaccine. Another unfortunate aspect of restricting vaccination to girls is that it focuses attention on women in relation to a sexually transmitted virus; this is not a useful social message in any context and there are some cultures in which the strategy may prove unacceptable.
Assuming efficacy in men is shown, I suggest that an ideal solution would be to vaccinate girls with Cervarix and boys with Gardasil. Evidence is accumulating to suggest that Cervarix may offer greater protection against cervical cancer, which would make it the more logical choice for girls. If boys were vaccinated with Gardasil they would improve herd immunity against the cancer-causing HPV types, while also being protected themselves (a particular benefit for MSM). Meanwhile, their vaccination against HPV types 6 and 11 would, again via herd immunity, protect both sexes. Finally, both sexes would be seen as susceptible, which, in my view, would be a far more equitable public health message.
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